The value of single nucleotide polymorphisms in genes of serum markers in breast cancer diagnostics
Completed
- Conditions
- breast cancermammacarcinoma10006291
- Registration Number
- NL-OMON32263
- Lead Sponsor
- Sint Antonius Ziekenhuis
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 858
Inclusion Criteria
Women older than 18 years with a breast lump
Exclusion Criteria
Patients are excluded if:
· they are male
· they are younger than 18 years
· they are unable to give informed consent due to other circumstances (delirium at admission, severe psychiatric disease)
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>· CA15-3, CEA, Her-2 and YKL-40 levels and its SNPs (measured in serum and<br /><br>cells collected from blood using immunochemical and molecular methods).<br /><br><br /><br>· To investigate whether the MUC1 568 A/G polymorphism in combination with<br /><br>CA15-3, the CHI3L1-329 G/A polymorphism in combination with YKL-40 and the<br /><br>Her2 I655V polymorphism in combination with Her-2 levels can increase its roles<br /><br>in primary screening and (early) detection of renewed breast cancer activity<br /><br>in the follow-up after curative treatment.</p><br>
- Secondary Outcome Measures
Name Time Method <p>· To investigate differences in genotype and serum marker levels between<br /><br>premenopausal and postmenopausal women<br /><br><br /><br>· To investigate whether (combinations of) SNPs are associated with prognostic<br /><br>factors like tumour size, tumour grade and nodal involvement<br /><br><br /><br>· To explore serum markers and its SNPs appearing in scientific literature as<br /><br>promising diagnostic tests during the course of the study (addendum needed)<br /><br><br /><br>· To establish functional consequences of SNPs of genes of serum marker in<br /><br>relation with tumour specific therapy</p><br>
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms link SNPs in serum marker genes to breast cancer diagnostics in NL-OMON32263?
How do SNPs in serum marker genes compare to standard-of-care diagnostics for breast cancer in terms of sensitivity and specificity?
Which specific serum biomarkers and SNPs are being evaluated for patient selection in the Sint Antonius Ziekenhuis breast cancer trial?
What adverse events are associated with SNP-based diagnostic approaches in breast cancer, and how are they managed in clinical practice?
Are there combination strategies involving SNP analysis and other biomarkers for HER2-negative or triple-negative breast cancer subtypes in observational studies?